Skip to content
lifestyle.projectdiaspora.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Xilio Therapeutics, Inc.
Xilio Therapeutics Appoints Ben Harshbarger as Chief Legal Officer
June 29, 2026
Xilio Therapeutics Reports First Quarter 2026 Financial Results and Provides Pipeline and Business Updates
May 20, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 7, 2026
Xilio Therapeutics Announces New Preclinical Data at AACR Annual Meeting for XTX601, a Masked T Cell Engager Targeting CLDN18.2
May 4, 2026
Xilio Therapeutics Appoints Cheryl R. Blanchard, Ph.D. to its Board of Directors
May 4, 2026
Xilio Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 3, 2026
Xilio Therapeutics Announces Pipeline and Business Updates and Fourth Quarter and Full Year 2025 Financial Results
May 1, 2026
Xilio Therapeutics to Present New Preclinical Data for its Masked T Cell Engager Program Targeting CLDN18.2 at the American Association for Cancer Research (AACR) Annual Meeting
April 30, 2026
Xilio Therapeutics Announces 1-for-14 Reverse Stock Split
April 29, 2026
Xilio Therapeutics to Present at the Leerink Partners Global Healthcare Conference
March 2, 2026
1
2
Next Page
→